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Abstract 
The pathological features of Alzheimer’s disease (AD) have been researched and 
documented extensively, however the causes of these features are still unknown. The 
following studies sought to determine if epigenetic methylation alterations contribute to 
AD. Two studies were sequentially carried out, first using an IMR-32 model and then 
using a transgenic mouse model overexpressing beta-amyloid. A few assay and 
confirmation methods were carried out to determine the promoter regions in disease state 
models undergoing drastic change, and the genes linked to these promoter regions were 
analyzed to determine significant gene ontology being altered by this epigenetic 
modification. This data was further assessed in the transgenic mouse study by 
determining expression levels and transcription factor enrichment in the genes 
experiencing significant promoter methylation alterations. Both studies provided data 
supporting the idea that epigenetic methylation alterations are linked to genes having 
ontological functions associated with AD pathology. This conclusion supports the theory 
that epigenetics contributes to the development of AD.  
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Introduction 
 
Alzheimer’s Disease  
Alzheimer’s disease (AD) is characterized by terminal tissue damage due to two 
main pathological findings: beta amyloid plaques and neurofibrillary tangles. Amyloid 
beta plaques (Aβ) are insoluble aggregates that develop due to overproduction of amyloid 
beta peptides, which ultimately leads to neuronal degeneration [1 Selkoe, 1991 #2]. 
Neurofibrillary tangles (NFTs) are the result of abnormal phosphorylation of the protein 
tau [2]. Tau is a microtubule-associated protein that is designed to help in the promotion 
and stabilization of microtubules to allow for proper axonal transport in neurons. The 
pathological phosphorylation of tau seen in AD inhibits it from supporting these 
necessary cellular functions and inversely causes neuronal cytoskeletal disassembly [3, 
4]. These pathological findings have provided insight into what causes neurodegeneration 
to take place, however the causes of these characteristics and others seen in AD remain 
obscure.  
Epigenetics  
Evidence from past research seems to describe an epigenetic element to the 
development of AD. Epigenetics is defined as alterations in the transcription of an 
organism’s genome due to factors that are outside the DNA sequence. In other words, 
epigenetics turns gene expression on and off to help in the development and life cycle of 
an organism. There are several types of epigenetic modifications that work to alter 
genomic transcription including histone acetylation, nucleosome placement, and DNA 
methylation, the last of which will be investigated extensively throughout this study. 
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DNA methylation is when a methyl (CH3) group is chemically attached to the 
fifth carbon of a cytosine by enzymes known as DNA methyltransferases [5]. DNA 
methylation specifically targets the cytosine of the 5’-CpG-3’ dinucleotide, which have 
been determined to be present in high volume in 40% of human gene promoter regions 
[6]. These 5’-CpG-3’ rich promoter regions are known as CpG islands and these 
promoter regions characteristically contain low levels of DNA methylation [6]. 
Epigenetic methylation can impact genomic transcription through different mechanisms. 
First, the presence of methylation can prevent transcription factors from being able to 
bind to the promoter region of a gene, therefore inhibiting transcription. This mechanism 
is seen in transcriptional repression of the Foxp3 gene by DNA methylation in the 
promoter region [7]. Another mechanism is through promoting the binding of 
transcriptional repressors, which also inhibit transcription. For example, CpG methylation 
is required for the MeCP2 repressor protein to bind DNA and inhibit transcription [8]. 
The third mechanism by which methylation can inhibit transcription is through blocking 
progression of RNA polymerases [8]. Due to these consequences being the most 
prominent effect of DNA methylation, this epigenetic marker has been associated to 
transcriptional repression and gene silencing [9]. Nonetheless, exceptions are to be 
expected [10]. 
Epigenetics and Disease  
Alterations in epigenetic markers and therefore genomic transcription is 
biologically normal throughout the life cycle of an organism due to different gene 
products being needed at different times [11]. However, past research has proven that 
epigenetic alterations are also involved in the development of disease states such as 
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cancer and syndromes linked to mental retardation [5]. Disease linked epigenetic 
alterations have been found to yield hypomethylated and hypermethylated promoter 
regions, although the prior is more typical of overall genomic alterations [12, 13]. For 
example, cancer occurs when cells reproduce uncontrollably and avoid programmed cell 
death [14]. Abnormal epigenetic methylation leads to this pathological state due to its 
transcriptional impact on oncogenes and tumor suppressor genes. Oncogenes are genes 
that signal the cell to reproduce constantly. Therefore, when the promoter region of these 
genes is hypomethylated, transcription is not repressed through one of the mechanisms 
described previously, leading to increased expression causing the cell to constantly 
proliferate [15]. Hypermethylation has been found in the promoter region of tumor 
suppressor genes, leading to decreased expression of gene products that keep dangerous 
cells from becoming cancerous [16]. This substantiates the fact that the relationship 
between alterations in the epigenetic methylation of promoter regions of the genome 
deserve and disease development deserve substantial research. It is important to note that 
global hypomethylation is seen in disease states due to this allowing for proliferation of 
cells, as opposed to hypermethylation which causes gene silencing that would ultimately 
lead to cell and organismal death if the genome was becoming globally hypermethylated. 
Epigenetics and Alzheimer’s Disease  
Several factors contribute to the theory that epigenetic alterations, such as DNA 
methylation, play a role in the development of AD. First, over 90% of AD cases are late 
onset and appear to be sporadic, meaning that no genetic cause has been determined [17]. 
To expound on this factor, a non-Mendelian mode of acquiring AD is proposed due to the 
fact that twin studies looking at the development of AD show differing results [18-20]. 
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These studies suggest that DNA sequence alone does not lead to AD development. 
Second, research describes a parent-of-origin effect in AD, meaning that several genomic 
regions are passed down from the mother to affected individuals [21]. The most common 
method by which parent-of-origin effects are produced is mediated by DNA methylation, 
the focus of this study [22]. This environmental contribution, the maternal germ line, 
follows the mechanism of an epigenetic impact because it is outside the genetic code of 
an individual [23]. Third, mouse and human studies provide evidence that DNA 
methylation is altered between affected and control counterparts on a genomic level in 
DNA obtained from regions of the brain affected by AD [24]. While there were 
significant changes in diseased parts of the brain, methylation levels from unaffected 
regions of the brain remained unchanged between the affected and control counterparts. 
This specificity appears to be direct evidence that DNA methylation is involved in AD 
pathology. A fourth factor providing evidence for an epigenetic link to AD development 
is the fact that several genes that have been linked to AD pathology, such as APP, β-APP 
cleaving enzyme, and neprylisin, are transcriptionally regulated by DNA methylation in 
their promoter regions [25, 26]. Interestingly, although global hypomethylation is linked 
to AD, the neprylisin promoter is actually hypermethylated leading to its transcriptional 
silencing [26, 27]. This evidence displays the fact that although hypomethylation occurs 
on a global scale, hypermethylation may be seen when AD is studied in a gene-by-gene 
manner [26]. A final factor providing evidence for an epigenetic alteration contributing to 
AD pathology is the findings in a recent expression study showing over and under 
expressed mRNA levels from several genes that are associated with processes that are 
malfunctioning in AD [28]. These expression changes could be a result of epigenetic 
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changes in the promoter region of these genes. Together, these factors provide a strong 
argument for an epigenetic impact on the development of AD, but specific epigenetic 
effects have not yet been determined. If determined, these specific pathological 
alterations could not only give insight into the molecular pathology behind the 
development of AD, but they could also provide a signature to help in the early 
determination of AD, as well as in the target and development of future therapies. The 
hypothesis of this study is that various promoters in neurons affected by AD will display 
alterations in their methylation status, whether that be hypomethylation or 
hypermethylation, and that some of these promoter regions will be linked to genes that 
are associated to the pathology displayed in AD. 
It should be noted that previous studies have sought to determine transcriptional 
changes in the genome of in vitro and in vivo AD models developed through beta 
amyloid treatment. However, these models were limited due to using undifferentiated 
neuroblastoma cells [29] or due to the fact that only small portions of the genome were 
analyzed in studies using mouse models [30]. The models described in this study dismiss 
these previous limitations due to their complexity and entirety. First, a differentiated 
neuroblastoma cell line was studied on a genomic and gene-by-gene basis. Due to the 
positive results obtained from this first study, a second study was performed using a 
transgenic mouse model that once again worked towards the complexity of a human in 
vivo model and once again studied DNA methylation on a genomic and gene-by-gene 
basis. Therefore, this study sought not only to look at a model that more accurately 
resembles the genome of a human affected with AD, but also to determine the specific 
molecular functions impacted by epigenetic promoter-based methylation changes. 
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Determining Methylated Genomic Regions  
The basis of this study requires the ability to distinguish between the presence and 
absence of methylation in genomic regions. There have been several experimental 
methods used for determining the presence of DNA methylation, a few of which will be 
discussed here along with their positive and negative aspects. First, bisulfate sequencing 
is a method that uses sodium bisulfate to cause a reaction with unmethylated cytosine 
bases in a DNA strand resulting in sulfonated cytosine [31]. Once deaminated, the sulfate 
is removed from the produced sulfonated uracil. The DNA is then put through a 
polymerase chain reaction (PCR) that uses Taq polymerase, which identifies uracil as 
thymine. This causes the resulting PCR product to incorrectly display thymine at the 
genomic position of all unmethylated cytosines that have been converted to uracil [32]. 
However, methylated cytosine prevents the conversion of cytosine to uracil, resulting in 
PCR results that correctly label cytosine bases. This method is reliable, but impractical 
for genomic wide studies due to huge time and monetary requirements.  
A similar method uses bisulfite sequencing and primers to determine where 
methylation exists [33]. Templates are treated in the manner described above except that 
instead of using Taq polymerase, methylation-specific primers are used to bind to 
cytosines that remain after the bisulfite treatment due to methylative protection. A PCR 
product reveals that a region is methylated due to the implication that the primer was able 
to bind. However, this method is still impractical for a genome wide study. 
A third method takes advantage of the specific activity of methylation-sensitive 
restriction endonucleases (MSRE), which are enzymes that cut DNA specifically when 
certain methylation states exist [34]. Using two different MSREs that are isoschizomers 
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that both target 5’-CCGG-3’ sequences, the methylation status of a specific region can be 
determined. For example, HpaII recognizes and cuts 5’-CCGG-3’ sequences only when 
the cytosine is not methylated [34]. If the cytosine is methylated, it protects the DNA 
from enzymatic cutting by HpaII. However, MspI cuts the DNA strand regardless of 
whether it is methylated or not. Using a method called the HELP assay (HpaII tiny 
fragment Enrichment by Ligation-mediated PCR), the fragments from the MSRE 
digestions are co-hybridized to genomic microarrays [35, 36]. This allows for comparison 
of the methylation status of intergenomic and intragenomic regions on a genome wide 
scale making the HELP assay a practical and reliable method for genomic wide analysis 
[37]. For this reason, this method was used in both the in vitro and in vivo models of the 
presented study. However, there are limitations of this method that should be noted. First, 
the HELP assay is limited to assessing the methylation status of CpG sequences that 
reside in the restriction site 5’-CCGG-3’. Any methylation that exists on cytosine bases 
outside of this sequence cannot be detected by this method. Also, this method requires a 
fragment that is less than 2kb in size because fragments longer than that will not be 
amplified by ligation-mediated PCR (LM-PCR) and therefore would not show up on the 
microarray data. It is also likely that very small fragments (<20 base pairs) with high 
internal complementarity will not ligate to LM-PCR primers due to their secondary 
structure.  
The final method for methylation determination that will be discussed is called 
methylated DNA immunoprecipitation (MeDIP). This method uses an antibody to 
specifically bind to methylated cytosines of fragmented DNA and allow for separation 
from the rest of the DNA [38]. These separated fragments are then determined by 
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hybridization to a genomic chip array, which, like in the HELP assay method, makes this 
a practical approach to determining methylation statuses in a genome wide study. The 
MeDIP method does not have the limitation for there to be a 5’-CCGG-3’ sequence due 
to the antibody only requiring cytosine methylation to allow it to bind. This method also 
eliminates the problem of inadequate fragmentation because it uses sonification, a 
technique that shreds the genome into many smaller fragments (200-1000 base pairs). 
Nonetheless, the HELP assay is more efficient at picking up small fragments due to the 
complex purification process of the MeDIP method, which could cause failure to detect 
CpG regions that are significant in the molecular processes causing development of AD. 
Regardless of its ability to have a broad and narrow focus as well as being reliable, due to 
expense, this method was only used in the in vivo transgenic mouse study.  
One pitfall of both of the methods that were used (HELP assay and MeDIP) is 
that some CpG regions that demonstrate an altered methylation status may ultimately not 
regulate the transcriptional level of a nearby gene or the local chromatin structure. With 
that said, the altered methylation pattern could still serve as an indicator of AD 
development.  
Alzheimer’s Model Used for Each Study  
IMR-32 cells were grown by ATCC prior to purchase using methods previously 
reported [39]. The IMR-32 cell line was chosen to serve as the in vitro cell model, which 
was completed prior to the start of the in vivo study. The IMR-32 cell line was chosen 
due to having the ability to be differentiated into cholinergic neuronal cells [40]. This 
type of neuron has receptors for acetylcholine and is able to secrete the Aβ protein, a 
function that is disrupted in AD leading to harmful effects caused by beta amyloid 
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aggregates. A portion of the differentiated IMR-32 cells was treated with Aβ protein to 
function as an AD model [26], while another portion of IMR-32 cells was left 
undifferentiated to act as a control for the differentiation procedure.  
The in vivo model that was studied after completion of the in vitro model study 
consisted of two strains of mice obtained from the Jackson Laboratory. The first strain 
(B6SJL-Tg[APPSwFlLon,PSEN1*M146L*L286V]6799Vas/Mmjax) expresses two 
transgenes regulated by neural-specific elements to limit the overexpression to the brain. 
Expression of mutant Amyloid Precursor Protein (K670N, M671L, I716V, and V717I) 
and mutant Presenilin1 (M146L and L286V) results in the accelerated deposition of the 
42 amino acid form of beta amyloid [41]. This provides pathology which mirrors that 
displayed in AD patients. These mice have memory impairment in the Y-maze test and 
recapitulate many of the major features associated with AD as reported by the Mutant 
Mouse Regional Resource Centers. The other strain used in this study does not express 
the transgenes but is of the same genetic background (B6SJL) to allow it to act as an 
accurate control. All mice used are age-matched and obtained from the Jackson 
Laboratory as adults (9-10 months old). 
Materials and Methods 
Brief Procedural Overview  
The first step in the in vitro (IMR-32) study was the culturing and differentiation 
of the cell model. This step was unnecessary in the in vivo (transgenic mouse) study due 
to the mice being pre-prepared by the Jackson Laboratory. After this process, in both 
studies, the cells were harvested and the DNA was isolated and purified using the 
procedure described below. Once isolated, the DNA was digested with HpaII and MspI, 
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which are MSRE isoschizomers, to fragment the DNA based on the methylation status of 
5’-CCGG-3’ sequences. These fragments were then amplified using a method called the 
HELP assay, which as discussed previously, attaches adapters of known sequence onto 
the ends of fragments allowing for primer facilitated amplification. These amplified DNA 
samples from both studies were sent to professional laboratories, where they were 
fluorescently labeled and co-hybridized on promoter microarrays. Computer software 
was used to measure fluorescence and subsequently determine and graph HpaII/MspI 
ratios for each probe. This NimbleGen provided data was confirmed through PCR 
analysis of randomly chosen regions. The genomic regions with extreme methylation 
changes between control and disease state were linked to nearby genes, which were then 
linked to ontological function. A second method of analyzing DNA methylation in 
genomic promoter regions, MeDIP, which was discussed previously, was subsequently 
performed only in the transgenic mouse study. DNA was shredded into fragments using 
MseI and then treated with an antibody that binds to fragments by way of their 
methylated cytosines. The fragments that are bound by the antibody were then expressed 
as a purification enrichment by again using an outside laboratories microarray 
hybridization procedure. This data was analyzed by computer software based on 
fluorescence and revealed regional peaks of methylation change, which was once again 
confirmed through PCR analysis and assessed for significant gene ontology associations. 
Isolation and Purification of IMR- 32 DNA  
After the IMR-32 cells were grown by and purchased from ATCC, the cells were 
subsequently depleted of fibroblasts using immunomagnetic anti-fibroblast microbeads 
and LD MACS separation columns as was recommended by the manufacturer. Three 
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plates containing IMR-32 neuroblastoma cells were grown in proliferation medium 
(DMEM with glutamax, 5% FCS, 100 U/ml penicillin-streptomycin, and 10 ug/ml 
gentamicin) at 37C and 5% CO2 for two days at a density of 5 x 106 cells/15 cm plate. 
Two plates were then grown in differentiation media (DMEM with glutamax, 2% FCS, 
2mM sodium butyrate, 100 U/ml penicillin-streptomycin, and 10 μg/ml gentamicin) for 
seven days to allow for differentiation into mature neuronal cells. The last plate of 
undifferentiated neuroblastoma cells was maintained in culture as a control for the 
differentiation protocol. After the differentiation, one of the two plates was maintained, 
and the other was treated with 25 μM AB1-40 peptide, as was previously reported [26], for 
2 days to provide a model with one of the major pathological features of AD. The cells 
were washed with cold PBS and isolated by scraping and centrifugation. 
The nuclei pellets were stored at 80°C until the DNA extraction procedure was 
carried out. At this point, approximately 100 μL of each type of nuclei pellet was thawed 
and 478 μL of stop buffer [20% SDS; 5M NaCl; 0.5M EDTA], 20 μL protease K 
[2.5mg/mL], and 2 μL RNase A [10mg/mL] were added. After gentle mixing, the 
samples were incubated overnight in a 42°C hot water bath to allow for complete 
degradation of cellular protein. 500 μL of PCIAA (Phenol-chloroform-isoamyl alcohol) 
was added to each, followed by gentle mixing and incubation on a rotary wheel at 37°C 
for 10 minutes. The samples were then centrifuged at 17,000xg for 5 minutes to cause 
separation into aqueous and organic layers. The aqueous layer from each sample, about 
400 μL, was transferred to a new eppendorf tube and saved. This PCIAA purification step 
was repeated two more times for each sample. 
 The DNA was precipitated in each sample by adding NaOAc [3M] (equal to 
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1/10th sample volume), 100% ethanol (equal to 3x sample volume), and 1 μL of glycogen 
[20mg/mL]. The DNA in each sample was then pelleted by mixing and centrifuging at 
17,000xg for 1 hour. The supernatant was removed through careful suctioning, and the 
DNA pellet was washed with 70% μL ethanol. The pellets were then resuspended in 200 
μL deionized (DI) water. The DNA was stored at -20°C to protect from degradation. The 
concentration of the DNA in each sample was found using UV spectroscopy. 
Isolation and Purification of Transgenic Mouse DNA  
The in vivo model (transgenic mouse model) was ordered from Jackson 
Laboratory with all treatment and tests previously performed. The mice were kept for 
several days to determine that the mice were otherwise healthy in order to prevent any 
secondary health problems from skewing the data. After this time period, the mice were 
euthanized using CO2 and decapitated. The brain was isolated immediately, sliced 
longitudinally, and placed in 60 mL of room-temperature 80% ethanol for 40 minutes, 
The hippocampi were then aseptically dissected on an ice-cold sterile platform. Both 
sides of the brain were kept on ice the entire time. The hippocampi were stored dry at -
80°C. The DNA was then isolated from the control and disease state cells and purified 
using almost the same procedure as was described previously for the in vitro study except 
for two things. First, the pK stock used during the isolation of DNA was 20 mg/mL 
instead of 2.5 mg/mL as was used in the IMR-32 DNA isolation. Also, 1 μL of RNase 
and 10 μL of pK were added halfway through the isolation reaction to allow for more 
complete degradation. 
HELP Assay  
Portions of the DNA from all samples of both the IMR-32 and in transgenic 
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mouse study were digested with either HpaII or MspI MSREs. The HpaII digestion 
reactions consisted of 1 µg of DNA, 4 µl of HpaII (10,000 U/ml), and 20 µl of New 
England Biolabs Buffer 1, and the MspI digestions consisted of 1 µg of DNA and 2 µl of 
MspI (20,000 U/ml) with 20 µl of NEB 4. Both reactions were raised to final volumes of 
200 µl using DI water. The digestion was then allowed to incubate overnight in a hot 
water bath at 37°C. The digested DNA was then purified using the methods described 
previously and resuspended in 15.5 µl of 10 mM Tris-HCl (pH 8). 
Ligation of adapters to allow for PCR amplification of the digested DNA was 
carried out using two double stranded adapters, JHpaII and NHpaII. These adapters were 
added to the DNA at concentrations of 40 mM each and were ligated to the ends of the 
fragmented DNA using T4 DNA ligase. The sequence of JHpaII is 5’-
CGGCTGTTCATG-3’ annealed to 5’-CGACGTCGACTATCCATGAACAGC-3’, and 
the sequence of NHpaII is 5’-CGGCTTCCCTCG-3’ annealed to 5’-
GCAACTGTGCTATCCGAGGGAAGC-3’. The ligation reaction was carried out in 
PCR tubes and consisted of 6 µl of 5× T4 ligase buffer (250 mM Tris-HCl (pH 7.6), 50 
mM MgCl2, 5 mM ATP, 5 mM DTT, 25% (w/v) polyethylene glycol-8000, Invitrogen), 
15.5 µl digested DNA, 4 µl of 50 µM pre-annealed JHpaII linkers, 4 µl of µM pre-
annealed NHpaII linkers, and 1 µl of T4 DNA ligase (4 U/ µl). The reactions were put in 
a thermocycler at 16°C overnight. The reactions were then diluted to 10 ml by 10 mM 
Tris-HCl (pH 8). 
For the ligation mediated PCR, twice as much digested DNA was used for HpaII 
samples than was used for MspI samples due to differences in the digestion products. The 
MspI digestion causes more complex fragments that result in quicker amplification and 
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therefore premature saturation. This would mean unwanted elements developed during 
“excess” PCR cycles could contaminate the solution. However, the decreased DNA 
content in the MspI samples eliminated this problem. The LM-PCR reaction contained 5 
µl of HpaII digested DNA or 2.5 µl of MspI digested DNA, .5 µl of JHpa 24-mer 
oligonucleotide, .5 µl of NHpa 24-mer oligonucleotide, 25 µl of Supermix (Bio-Rad), and 
brought to a final volume of 50 µl with DI water. The two longer primers will be used to 
amplify 1/50 of the ligated fragments by qPCR using EvaGreen Supermix (Biorad). The 
following cycle arrangement was used: 10 minutes at 72°C, 20 cycles of 30 seconds at 
95°C and 3 minutes at 72°C, and a final 10 minutes at 72°C.  
After another purification process using a Qiagen QIAquick PCR purification kit, 
the DNA samples from both studies were measured out into portions equaling final 
masses of at least 4 µg of DNA and concentrations of at least 250 ng/µl. The DNA 
fragments from each DNA sample (2 IMR-32 undifferentiated, 2 IMR-32 differentiated, 
1 IMR-32 Aβ treated) were fluorescently labeled and hybridized to promoter arrays 
manufactured by NimbleGen (2.1M Deluxe Promoter Array). These arrays contained 
DNA sequences representing 10kb of all annotated promoters (spanning from 7kb 
upstream and 3kb downstream of the transcription start site) and included 28,266 CpG 
clusters and 475 miRNA transcripts. 
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Figure 1. HELP Assay Overview. DNA was isolated from IMR-32 undifferentiated, 
differentiated, and beta amyloid treated cells as well as from hippocampal cells from 
transgenic mice overexpressing beta amyloid and their control counterparts. The DNA 
was either digested with HpaII or MspI and then ligated to adapters of known sequence 
using Taq polymerase. The DNA was amplified using LM-PCR and then sent to 
NimbleGen (IMR-32) or Arraystar (Transgenic Mice) where it was fluorescently labeled 
and hybridized to a promoter microarray. Probe fluorescence was measured and 
HpaII/MspI probe value ratios were analyzed and graphed using Matlab 2011. 
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HELP Assay Microarray Analysis for IMR-32 Study  
Matlab 2011 was used for the analysis of the raw microarray data. Briefly, the 
pairwise data files supplied by ArrayStar were used to calculate the log ratio data (HpaII / 
MspI) for each array. Mean centered histograms were generated from the log ratio data. 
Since MspI fragments represent the universe of possible fragments, array regions that 
failed to give a signal in the MspI sample were excluded from the analysis. The ratio 
values were then subjected to lowest normalization and the arrays were normalized to 
each other using equivalent sum of squares scaling. An error model was generated using 
a 600 base pair moving window with 150 base pair steps in which both the mean probe 
log ratio and p-value were calculated for each window. [42] This method summarized the 
local intensity of amplified fragments when multiple oligonucleotides were representing 
the fragment. All p-values were calculated using a nonparametric Wilcoxon signed-rank 
test. In order to establish an initial significant ratio threshold (for hypermethylated and 
hypomethylated designations), an HpaII / MspI log ratio density plot was generated and 
averaged across all array replicates. Subsequently, due to there being only 1 sample of Aβ 
treated, this data was not averaged with any other data set. This type of plot produced a 
bimodal distribution of ratio occurrences and allowed a log ratio threshold to divide the 
two modes [37]. Genomic regions that contained ratios greater than this threshold and 
have a p-value <0.05 were designated as hypomethylated regions. Genomic regions that 
contained ratios less than this threshold and have a p-value <0.05 were designated as 
hypermethylated regions. The most changing 0.1% of all the regions, the 0.05% of 
regions undergoing the most loss of methylation, and the 0.05% of regions undergoing 
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the most gain of methylation, were chosen as the regions of interest for this study due to 
this list’s extreme stringency (refer to Figure 3). 
HELP Assay Microarray Analysis for Transgenic Mouse Study  
After amplification by LM-PCR as was described previously, the DNA from the 
control and disease-state transgenic mice was again purified, as in the IMR-32 study, and 
measured out to final masses of at least 4 µg of DNA and concentrations of at least 250 
ng/µl, as specified by the microarray manufacturer. The DNA fragments from each DNA 
sample (2 control transgenic mice and 2 disease-state transgenic mice) were fluorescently 
labeled and hybridized to promoter arrays. This study used a different type of NimbleGen 
promoter array, Multiplex MM9 CpG Promoter Array, which is designed for mouse 
genomes. These arrays contained DNA sequences representing 20,404 annotated 
promoters (spanning from 3kb upstream to 0.7kb downstream of the transcription start 
site) and included 15,980 CpG islands. This data was assessed using Matlab 2011, as 
previously described for the IMR-32 study.  
Gene Ontology Assessment for HELP Assay in Both Studies  
Gene symbols were linked to the 0.1% most changing microarray probes, 0.05% 
probes becoming hypomethylated and 0.05% probes becoming hypermethylated, by 
plugging the region of that probe into GREAT, a region/gene association and annotation 
software developed by Stanford University and Bejerano Lab. Human genome 18 was 
used for the species assembly in the IMR-32 study, and mus musculus 9 was used for the 
species assembly in the transgenic study. The whole genome was used for the 
background regions. This software developed graphs representing the number of 
associated genes per region, distance to TSS, and absolute distance to TSS. Under the 
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global controls options, “View all region-gene associations” was chosen to obtain all of 
the gene symbols for the inputted regions. These gene symbols were then plugged into 
GeneCodis, a gene annotation website; homosapiens was used as the organism and 
biological processes was selected for genome wide assessment. The gene symbols linked 
to the 0.05% probes becoming most hypomethylated, the 0.05% probes becoming most 
hypermethylated, and a random list of genes of equal size to the lists being evaluated 
were assessed using the following G.O. requirements: level 7 (the most stringent), a 
minimum of 3 genes associated with that ontology, and a chi square value that was lower 
than the lowest obtained chi square value from the random list that was associated with 
specific ontology topics. These topics included neurological related functions and 
apoptosis. False discovery rate was used to find a corrected chi square value. The 
enrichment value was calculated by dividing the ratio of genes for a gene ontology 
category in the list to the total number of genes in the list by the ratio of genes for that 
gene ontology category in the genome to the total number of genes in genome as 
demonstrated by the following formula: 
�
Number of Genes for G.O. in List
Number of Genes in List �
�
Total Number of Genes for G.O.
Total Number of Genes in Genome�
 
The gene ontologies that met these requirements were charted along with their linked 
gene symbols and calculated chi-square and enrichment value. [42] 
MeDIP Assay for Transgenic Mouse Study  
A portion of the DNA isolated from the transgenic mice was also assessed using 
methylated DNA immunoprecipitation. Instead of digestion with HpaII and MspI, the 
DNA from the 2 control and 2 AD mice was sent to Arraystar in total amount and 
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concentration equal to that of the HELP assay microarray procedure. It was then shredded 
into fragments of about 200-1000 base pairs using sonification. Immunoprecipitation of 
methylated DNA fragments was carried out using Biomag magnetic beads coupled 
mouse monoclonal antibody that binds to methylated cytosine. Control sequences were 
mixed in with the genomic fragments. The immunoprecipitated DNA was isolated from 
the unbound DNA and purified as previously described using phenol chloroform 
extraction and ethanol precipitation.  
The methylated DNA fragments were then fluorescently labeled with Cy3- and Cy5-
labeled random 9-mers. These fragments were hybridized to NimbleGen Mouse 3x720K 
Promoter Plus CpG Island Arrays, which is a single array design that includes 15,980 
CpG Islands and 20,404 RefSeq gene promoter regions (from about -2960bp to +740bp 
of the TSSs). This array contained a total of approximately 720,000 probes. An Axon 
GenePix 4000B microarray scanner was used to scan and compute the fluorescence given 
off by each probe.  
MeDIP Microarray Analysis for Transgenic Mouse Study  
Differentially methylated regions were determined by performing a T-test on 
different groups of replicate samples to calculate the p-value for each probe. Those p-
values <0.05 were defined as differentially methylated probes, which were then further 
analyzed to find differentially methylated regions (DMR). Simply stated, the DMRs are 
those regions that show significant changes in the methylation status of a sequence of 
probes’ values between the control and AD genome. All of the DMRs between both 
assays were combined into one list that provided the region of the genome where the 
peak of changing probes exist, the gene symbol that this region is linked to, NM and NP 
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Figure 2. MeDIP Assay Overview. DNA was isolated from hippocampal cells from 
transgenic mice overexpressing beta amyloid and their control counterparts. This assay 
was not carried out in the IMR-32 study. The DNA was then sonicated into fragments of 
200-1000 base pairs. Methylated fragments were isolated using a monoclonal antibody 
that binds to methylated cytosines. These fragments were sent to ArrayStar where they 
were fluorescently labeled and hybridized to a promoter microarray. Fluorescence was 
measured and regions with significant changes in methylation levels were reported.  
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numbers, the assay that the data came from, and the distance of the DMR from the 
transcription starts site (TSS) and transcription termination site (TTS). Once this data was 
provided by Arraystar, the list of DMRs was narrowed down using Microsoft Excel 2010 
to only those genes that were linked to DMRs in their promoter regions that were mapped 
to within 500 base pairs of each other in both assays. 
Gene Ontology Assessment for Transgenic Mouse Study  
Genecodis, a gene annotation website, was again used. However, the use of 
GREAT was not necessary for this assay due to the DMRs being previously linked to 
their associated genes. Mus musculus was used as the organism and biological processes 
was selected for genome wide assessment. The gene symbols of the regions becoming 
more hypomethylated, more hypermethylated, and a random list of equal size to the lists 
being evaluated were assessed using the same G.O. requirements as in the HELP assay. 
The random list was pulled from a list of all gene-linked promoter transcripts provided by 
Arraystar. False discovery rate was again used to find a corrected chi square value, and 
the enrichment value was calculated using the same formula presented previously. The 
gene ontologies that met these requirements were charted along with their linked gene 
symbols and calculated chi-square and enrichment value. 
Confirmations of Microarray Data in Both Studies  
MSRE digestion and qPCR analysis of digested DNA were used to confirm the 
HELP and MeDIP microarray data from both studies. Some regions that were confirmed 
in the IMR-32 study were randomly chosen, while others were chosen based on having 
significant biological functions as discovered in the gene ontology assessment. The 
randomly chosen regions were pulled from a list of the most changing 0.1% of all the 
EPIGENETIC REMODELING IN AD  
 
27 
regions, the 0.05% of regions undergoing the most loss of methylation, and the 0.05% of 
regions undergoing the most gain of methylation. All of the confirmations carried out in 
the transgenic study were specifically chosen based on significant biological function. All 
of the confirmations focused primarily on the change between the HpaII/MspI ratio 
between control and AD DNA.  
To carry out these qPCR site-specific confirmations, primers were designed using 
the UCSC genome browser, ApE, and Primer3. The UCSC genome browser was used to 
determine the specific DNA sequence around the probe or of the region being confirmed. 
ApE (A Plasmid Editor) was used to highlight the 5’-CCGG-3’ sequences in the region 
being confirmed. The primers were then designed using Primer3 (http://biotools.umass 
med.edu/bioapps/primer3_www.cgi). They were specifically designed around the 5’-
CCGG-3’ sequence nearest the probe or probes showing extreme change in their 
methylation status. The primers were designed around this sequence specifically because 
it is targeted and shredded by the enzymes being used based on the methylation status. 
The specific requirements set while designing the primers were as follows: product size 
range was chosen to be between 80-140 base pairs, the primer Tm was 60±2, and the 
primer size was 20±2 base pairs. All other criteria were left as the default settings by the 
software. The following stipulations were required for a region to be confirmation 
qualified: a CCGG close to a changing probe and the possibility for primer design within 
the previously stated primer design requirements. 
The control and Aβ DNA from both studies were digested with HpaII, MspI, and 
50% glycerol (to act as a control) in separate reactions. The HpaII digestion reactions 
consisted of 2 μg of DNA, 8 μL of HpaII, 40 μL of NEB Buffer 1, and raised to 200 μL 
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using DI water. The MspI digestion reactions consisted of 2 μg of DNA, 4 μL of HpaII, 
40 μL of NEB Buffer 1, and raised to 200 μL using DI water. The glycerol control 
reaction mirrored the MspI reaction except that it contained 2 μL of 50% glycerol instead 
of MspI. These digestion reactions were incubated overnight in a hot water bath at 37°C 
and then purified using the PCIAA procedure described previously. The samples were 
stored at -20°C after being raised to 200 μL in DI water. 
The qPCR confirmation reactions performed in a BioRad MJ Mini Personal 
Thermal Cycler contained the following: .015-.025 μg of either HpaII or MspI digested 
DNA or uncut DNA from the glycerol digestion, primer working stock that contained 
.625 μM of both the forward and reverse primer, 12.5 μL of BioRad Supermix. This 
reaction was raised to 25 μL in DI water. [42] Control reactions, which lacked DNA, 
were also run to confirm that primer self-annealing and amplification were not occurring. 
The touchdown PCR cycle started with a 5 minute melting step at 95°C. This was 
preceded by a cycle consisting of a 10 second melting step at 94°C, followed by a 30 
second annealing period at 69°C, and a 30 second extension step at 72°C. This cycle was 
repeated 19 times, but each time the annealing step decreased by .5°C. This was followed 
by a second cycle consisting of a 10 second melting step at 94°C, a 30 second annealing 
at 59°C, and a 30 second extension step at 72°C. This second cycle was repeated 24 
times, but the annealing step temperature was held constant. The touchdown qPCR 
reaction was concluded with a 5 minute extension step at 72°C. BioRad CFX Manager 
2.0 was used to develop amplification graphs. [42] To determine the cycle in which each 
of the DNA amplifications of a specific confirmation reached equivalent concentrations, 
a horizontal line was placed through the point at which each sample’s (uncut, MspI, and 
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HpaII) amplification was in its most linear phase. This was carried out for each of the 
confirmations, and the cycle quantification was recorded for use in graphing the 
difference between the HpaII and MspI amplification speeds. 
Results 
Aβ Induction Results in Little Genomic Scale Methylation Alteration  
Analysis of genome-wide promoter methylation levels provided by the microarray 
allowed for production of distribution graphs for the control and disease states of both 
models, representing hypomethylated and hypermethylated promoter CpG dinucleotides. 
These graphs plotted the control and Aβ microarray probe log2 HpaII/MspI ratios as 
frequency distributions and mean-centered all of the ratios at zero. Positive ratios 
represent loci that are less methylated than the mean, and negative ratios represent loci 
that are more methylated. The curves represent the probability of the data from each bin 
belonging to the corresponding peak. [42] The mean HpaII/MspI ratios of the control and 
diseased state peaks were calculated and are as follows: -0.66 and 1.76 for the control 
IMR-32 microarray, -0.76 and 1.95 for the Aβ treated IMR-32 microarray, -0.195 for the 
control transgenic mouse microarray, and -0.267 for the Aβ overexpressed transgenic 
mouse microarray. It should be noted that the IMR-32 study contained two peaks in each 
of the distribution graphs due to it being a cancer cell line. The epigenetic makeup is 
previously altered from the norm due to the cancer disease state. Therefore, the 
transgenic mouse model distribution graph, which contains only one peak, is a much 
more accurate representation of the epigenetic makeup before and after AD development. 
The distribution between the control and disease state in each model were extremely 
similar, with an r2 value of 0.978 for the IMR-32 study and 0.8763 for the transgenic 
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mouse study. Together, this data provides evidence that Aβ treatment does not have a 
large global impact on DNA methylation levels, but instead impacts a small number of 
gene promoter methylation statuses.  
Methylation Changes at Discrete Genomic Loci  
 
Due to the promoter methylation levels not showing a large impact on a genomic 
scale, these studies focus on the impact of epigenetic changes at specific genomic loci. To 
assess only the extreme changes at specific loci, a histogram was generated that plotted 
the difference resulting from the subtraction of the control microarray data from the Aβ 
treated microarray data in a log2 form. Ratios greater than zero illustrate probes becoming 
hypomethylated, and those less than zero illustrate probes becoming hypermethylated. 
This data works to further support the conclusion that little change is occurring on a 
genomic scale due to most of the data being around zero, therefore undergoing little 
change. It also displays those regions undergoing drastic change, highlighting the primary 
focus of these studies. 
Confirmations of randomly chosen regions in the IMR-32 study were performed 
after mapping the microarray region and designing primers around 5’-CCGG-3’ 
sequences in close proximity to probes undergoing extreme change. For example, primers 
were designed around a probe in the genomic region chr13:113568450-113569450, a 
region becoming hypermethylated according to the microarray data. qPCR resulted in 
amplification of HpaII digested control DNA that almost matched that of the MspI 
digested control DNA. This showed that this region contained little methylation in the 
control state due to HpaII being able to cut to almost the same extent as MspI, which can 
cut all the time regardless of methylation status. However, when the same qPCR reaction 
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was run with Aβ treated DNA, the HpaII digested DNA showed very slow amplification 
in comparison to the MspI digested DNA. This slow amplification was due to 
methylation blocking HpaII’s cutting ability, resulting in fewer fragments for 
amplification. This data suggests that the region is gaining methylation as a result of Aβ 
treatment. The opposite results were determined when site-specific qPCR was performed 
on chr17:54996867-54998139, a genomic region that was becoming hypomethylated 
according to the microarray (refer to Figure 3).  Random confirmations using qPCR, 
MSRE digested DNA and designed primers provided results showing that 44 of the 45 
confirmations supported the microarray data, giving further confidence in the microarray 
results (refer to Figure 5). Confirmations were then performed on 5’-CCGG-3’ located in 
promoter regions of genes linked to significant ontology categories provided by 
Genecodis, which also supported the microarray data. The significance of these 
epigenetic changes occurring in genes linked to significant ontological categories will be 
examined in the discussion. 
Promoter Methylation Changes Occur in Regions Proximal and Distal to the TSS  
As mentioned previously, GREAT, a region/gene association and annotation 
software developed by Stanford University and Bejerano Lab, mapped the distance of the 
regions of interest (most changing 0.1%) from the TSS (refer to Figure 4). This analysis 
gave a wide variety of results, as some regions were mapped further than 10k base pairs 
away from the TSS (e.g. DLX1), while others were mapped very close to the TSS (e.g. 
VHL). As expected, due to using microarrays that focused primarily on promoter 
proximal regions, many of the regions of interest showed changes occurring at promoter 
proximal positions. For example, 45% of the regions undergoing a loss of methylation 
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were located within 5k base pairs of the TSS, whereas only 16% of the regions gaining 
methylation were within this frame. [42] Future studies are needed to determine if certain 
loci are more inclined towards a certain type of disease-linked epigenetic shift. 
     
      
 
Figure 3. Confirmations of Randomly Chosen Region Showing Dramatic Change 
Support Microarray Data. qPCR was performed on MSRE digested control and Aβ 
treated DNA. A horizontal line was placed through the point at which each sample’s 
(uncut, MspI, and HpaII) amplification was in its most linear phase to allow for 
determination of amplification speed. The cycle numbers for DNA samples of the same 
type (control and Aβ treated) provided by the horizontal line were graphed, and this 
HpaII/MspI ratio was then graphed against the HpaII/MspI ratio of the opposite DNA 
sample. These graphs, as shown above, allowed for comparison of methylation 
(protection) levels between control and disease state, therefore displaying the change 
brought about by AD development. 
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Figure 4. Promoter Methylation Changes Occur at Positions Proximal and Distal to 
the TSS of a Gene. This graph displays the number of regions experiencing a specific 
type of change, either methylation increase or decrease, at specific distances from the 
TSS as provided by GREAT. The x-axis represents the distance from the TSS in which 
those regions fall, while the y-axis represents the number of regions in a certain distance 
grouping. The color distinguishes whether a gain or loss of methylation is occurring at 
that region. Blue represents methylation loss, and yellow represents methylation gain. 
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Figure 5. qPCR Confirmations of Regions Undergoing Change Support IMR-32 
Microarray Data. The graphs above represent the 45 confirmations that were performed 
on regions randomly selected from a list of regions undergoing the most change between 
control and Aβ treated microarray data. The y-axis represents the amount of relative 
protection (due to methylation) that a region contains. The columns immediately next to 
one another represent the data being compared. The white columns represent the relative 
protection that exists in the control state, and the black columns represent the relative 
protection in the Aβ treated state. The graph on the top (A) represents the regions 
becoming hypermethylated (gaining protection) due to Aβ treatment, while the graph on 
the bottom (B) represents the regions becoming hypomethylated (losing protection) due 
to Aβ treatment. 44 out of the 45 (97%) regions tested confirmed the microarray data.  
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Promoter Alterations Are Linked to Genes with Significant Ontological Functions  
Analysis of the ontological assignments linked to genes experiencing changes in 
their promoter methylation levels in both the IMR-32 model and the transgenic mouse 
model provided insight into functions being impacted by these alterations. Genecodis was 
used to assess the genes experiencing change in the HELP assays from both studies, as 
well as those in the MeDIP assay from the transgenic study. All of the lists showed genes 
involved in neuronal and cell fate functions, and the p-values of these results were 
compared to a random list to ensure mathematical significance (refer to Figures 6-8).  
 
Figure 6. Beta Amyloid Treated Cells Show Methylation Changes in Genes Linked 
to Apoptotic and Neuronal Functions. GREAT, a region/gene association software was 
used to determine the gene symbols that were linked to the 0.1% most changing promoter 
regions. Genecodis, a gene annotation website, was then used to determine the 
ontological functions associated with these gene symbols. The table contains ontological 
functions that were associated with the gene list and have p-values for functions of the 
same topic that were lower than in a random list. The “Genes Involved” column displays 
the genes linked to the ontology category in that row. The p-value and enrichment 
demonstrate the likelihood that these genes linked to the same ontological category would 
exist in the same list of this size. 
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Figure 7. Methylation Changes in Transgenic Mouse Model Demonstrated by the 
HELP Assay Results are Linked to Apoptotic and Neuronal Functions. This table 
demonstrates the ontological functions associated with genes linked to the regions 
showing the 0.1% most significant change from the HELP assay data in the transgenic 
mouse model. The genes linked to the listed ontological function are represented in the 
“Genes Involved” column. Refer to Figure 6 for details about p-value meaning and 
requirements, as well as enrichment calculations. 
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Figure 8. Methylation Changes in Transgenic Mouse Model Demonstrated by the 
MeDIP Assay Results Are Linked to Apoptotic and Neuronal Functions. The genes 
showing extreme change in their promoter methylation levels in the MeDIP assay in both 
experimental samples were assessed for ontological function using Genecodis. This list 
consisted of 223 genes with promoter regions becoming hypermethylated and 330 
regions becoming hypomethylated in their promoter regions. The genes linked to the 
listed ontological function are represented in the “Genes Involved” column. An excel-
generated random list of equal size to the ones being analyzed was used to set a standard 
for what p-values were to be considered significant. Refer to Figure 6 for details about p-
value meaning and requirements, as well as enrichment calculations. 
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Discussion 
 Several conclusions can be drawn from the results obtained from these studies of 
epigenetic alterations in promoter regions due to Aβ treatment or overexpression. First, 
global scale methylation levels are for the most part consistent between control and 
disease state models. The second conclusion pulled from these studies is that specific 
genomic loci do experience extreme promoter methylation changes due to Aβ treatment. 
The specificity of the alterations drew the focus of these studies to examining the impact 
of these changes. This leads to the last two conclusions, the latter of which will be the 
highlight of these studies. But the first calls for a brief mention, and that is the conclusion 
that epigenetic alterations happen all throughout the promoter region, regardless of 
distance to the TSS. As mentioned in the results, some regions undergoing change are 
located only a few hundred base pairs from the TSS, whereas others are around 15k base 
pairs away. However, the distal changes are also important due to evidence which shows 
that enhancer mechanisms can allow for distal regulation of gene transcription [43, 44]. 
Nonetheless, it should be mentioned that GREAT maps genes to the closest “canonical” 
TSS, so it may be closer to a different TSS that is not yet firmly established [42]. It 
should be noted that this data calls for more detailed research into genomic wide 
epigenetic alterations, rather than a promoter specific focus as this study carries out.  
 The last and most interesting conclusion is the ontological functions associated 
with the genes undergoing the most drastic promoter methylation alterations. As shown 
by Figures 6-8, all of the assays in both studies link the most significant changes to genes 
associated with neuronal and apoptotic processes. Due to these associations, it appears 
that epigenetic factors may be impacting AD pathology in a direct manner through 
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alterations in the normal transcription of several vital genes. To help highlight the 
importance of this finding, we developed models for how these epigenetic alterations 
may possibly change transcription and contribute to AD pathology.  
 For the IMR-32 study our model associates the alterations in the promoter regions 
of the DLX1, VHL, and PCNT genes to possible AD pathology. DLX transcription 
factors have been found to have a direct impact on the migration and differentiation of 
GABAergic interneurons [45]. In studies using DLX1/2 knockout mice, migrational 
disruption and premature neurite (axon and dendrite) growth were observed showing that 
activity of these neurons is necessary for proper migration and repression of neurite 
outgrowth in premature neurons. Ultimately, DLX1/2 help premature neurons keep a 
compact shape while migrating to allow for proper movement and placement. As for 
VHL, this gene is a tumor suppressor gene that down-regulates proliferation factors [46]. 
The last gene used to develop a model for the IMR-32 study is PCNT, which has been 
linked to promoting proper mitotic spindle assembly and metaphase progression in the 
cell cycle [47, 48]. In the IMR-32 study, DLX1 and VHL are becoming hypomethylated 
due to Aβ treatment, and PCNT is becoming hypermethylated. Therefore, our model 
suggests that transcriptional changes due to these epigenetic alterations would lead to de-
differentiation or regression of neurite outgrowth, due to overexpression of DLX1, and 
lack of production or division of neural precursor cells, due to overexpression of VHL 
and under expression of PCNT. However, the IMR-32 study did not assess the mRNA 
levels of these cells, therefore the epigenetic based transcriptional alterations are only 
proposed. Nonetheless, this model does demonstrate the need for further investigation. As 
for the transgenic study, similar results have been found showing that many genes linked 
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directly to neuronal and apoptotic functions undergo epigenetic methylation alterations 
due to Aβ overexposure. 
 In conclusion, these studies provide evidence that warrants further study into the 
epigenetic basis of AD pathology, as well as research delving into the causes of these 
alterations. The determination that epigenetics plays a direct role in the pathology 
associated with AD development, would provide a target for future therapeutic methods. 
If these therapies could reverse the epigenetic shifts, it would be speculated that the 
pathology resulting from these shifts could also be reversed. However, the cause must be 
determined before a therapy can be discovered. 
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